person · Reporting owner

Kairos-Actuate SPV, L.P.

Disclosed activity across 1 company

Tapewire entity: 88252
SEC CIK: 0001835962

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370	Director · 1.5% Owner	August 12, 2024	August 17, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACTUATE THERAPEUTICS, INC.

Report date August 12, 2024 · Filed August 17, 2024

Jointly reported with THOMSON TODD S, Kairos SPV Fund LLC, Kairos Venture Opportunities I, L.P., Kairos Venture Partners II, L.P.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

F4: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F8: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F9: 15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	OtherWarrant (Right to Buy) · Derivative	28,464	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 21 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 28,464 shares Expires not disclosed F8 · derivative.exercise_price: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares. F8 · price: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares. F8 · derivative.exercise_date: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares. F8 · derivative.expiration_date: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries C Redeemable Convertible Preferred Stock · Derivative	49,984	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 20 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 0 Underlying: Common Stock · 49,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · derivative.exercise_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · derivative.expiration_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries C Redeemable Convertible Preferred Stock · Derivative	24,138	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 19 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos-Actuate SPV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 24,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · derivative.exercise_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F7 · derivative.expiration_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative	132,908	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 18 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 0 Underlying: Common Stock · 132,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · derivative.exercise_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · derivative.expiration_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative	230,597	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 17 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos-Actuate SPV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 230,597 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · derivative.exercise_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F6 · derivative.expiration_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative	138,889	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 16 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 0 Underlying: Common Stock · 138,889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative	146,870	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 15 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVOI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 146,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative	69,445	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 14 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 69,445 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-2 Redeemable Convertible Preferred Stock · Derivative	726,163	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 13 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVOI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 726,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F4 · price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F4 · derivative.exercise_date: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F4 · derivative.expiration_date: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionSeries B-1 Redeemable Convertible Preferred Stock · Derivative	1,058,318	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 12 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,058,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F1 · price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F1 · derivative.exercise_date: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F1 · derivative.expiration_date: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	SaleCommon Stock	18,750	$8.00	$150,000.00	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 11 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 1,184,795 F8 · kind: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	OtherCommon Stock	28,464	$5.27	$150,005.28	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 10 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 1,203,545 F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	49,984	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 9 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 321,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	24,138	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 8 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos-Actuate SPV, L.P. Disclosed balance after: 254,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	132,908	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 7 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 271,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	230,597	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 6 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos-Actuate SPV, L.P. Disclosed balance after: 230,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	138,889	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 5 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos SPV Fund, LLC Disclosed balance after: 138,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	146,870	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 4 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVOI, L.P. Disclosed balance after: 873,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	69,445	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 3 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 1,175,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	726,163	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 2 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVOI, L.P. Disclosed balance after: 726,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 14, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	ConversionCommon Stock	1,058,318	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 1 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By KVP II, L.P. Disclosed balance after: 1,105,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date. F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase. Read SEC document
August 12, 2024 Filed Aug 17, 2024 01:12 UTC	ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370	GrantNon-Qualified Stock Options · Derivative	15,000	$0.00 Strike: $8.00	$0.00	Disclosure SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 22 THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F9 · derivative.exercise_date: 15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.